pfmdr1 Polymorphism | AL arm | ASAQ arm |
---|
Pre-treatment | Post-treatment | p value* | Pre-treatment | Post-treatment | p value* |
---|
n (%) | n (%) | | n (%) | n (%) | |
---|
pfmdr1 codon 184 | n = 79 | n = 46 | | n = 30 | n = 2 | |
Y184 | 30 (38.0) | 12 (26.1) | Ref | 12 (40.0) | 0 (0) | Ref |
184Y/F | 15 (10.0) | 16 (34.8) | 0.054 | 9 (30.0) | 1 (50.0) | 0.454 |
184F | 34 (43.0) | 18 (39.1) | 0.657 | 9 (30.0) | 1 (50.0) | 0.454 |
pfmdr1 haplotypesa | n = 79 | n = 46 | | n = 30 | n = 2 | |
NYD | 45 (57.0) | 28 (60.9) | Ref | 21 (70.0) | 1 (50.0) | Ref |
NFD | 49 (62.0) | 34 (73.9) | 0.746 | 18 (60.0) | 2 (100) | 0.597 |
- AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine
- *Statistical significance in risk of recurrent infection (reinfection or recrudescence) was determined by Fisher’s exact test; three post-treatment samples (two in the AL arm and one in the ASAQ arm) failed to amplify at one or more loci and are not included in corresponding single nucleotide polymorphism and haplotype counts
- aHaplotype percentages may not sum to 100% because all possible haplotypes from mixed infections (both wild type and mutants) were included in the construction of haplotypes